Secondary analysis of the phase 3 COURAGE trial in 1104 men with overactive bladder on BPH treatment: vibegron vs placebo showed minimal differences in residual urine and flow; urinary retention 0.9% vs 0.7%, with no bladder function safety signals.
Secondary analysisn = 1,104
Rovner et al. Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial